Trevena, Inc.: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{Use American English|date=October 2023}} | {{Use American English|date=October 2023}} | ||
{{Use mdy dates|date=October 2023}} | {{Use mdy dates|date=October 2023}} | ||
| Line 5: | Line 4: | ||
[[File:Trevena_logo.svg|Trevena, Inc. logo|thumb|right]] | [[File:Trevena_logo.svg|Trevena, Inc. logo|thumb|right]] | ||
'''Trevena, Inc.''' is | '''Trevena, Inc.''' is a [[biopharmaceutical company]] based in the [[United States]] that focuses on the development of novel [[therapeutics]] for the treatment of [[central nervous system]] (CNS) disorders. The company is known for its innovative approach to drug discovery, particularly in the area of [[G protein-coupled receptors]] (GPCRs). | ||
==History== | ==History== | ||
Trevena, Inc. was founded in 2007 by a team of scientists | Trevena, Inc. was founded in 2007 by a team of scientists and entrepreneurs with a vision to leverage cutting-edge research in GPCR biology to develop new therapies. The company was initially supported by venture capital funding and has since grown to become a publicly traded entity on the [[NASDAQ]] stock exchange under the ticker symbol TRVN. | ||
==Research and Development== | ==Research and Development== | ||
Trevena's research | Trevena's research and development efforts are centered around the modulation of GPCRs, which are a large family of cell surface receptors that play a crucial role in many physiological processes. The company employs a proprietary platform to design biased ligands, which selectively activate specific signaling pathways associated with GPCRs, potentially leading to improved therapeutic outcomes with fewer side effects. | ||
=== | ===Key Products=== | ||
One of Trevena's | One of Trevena's most notable products is [[oliceridine]], a novel [[opioid]] analgesic designed to provide effective pain relief with a reduced risk of adverse effects commonly associated with traditional opioids, such as [[respiratory depression]] and [[constipation]]. Oliceridine has been approved by the [[U.S. Food and Drug Administration]] (FDA) for the management of acute pain in adults. | ||
== | ==Pipeline== | ||
Trevena is | Trevena continues to advance its pipeline of drug candidates targeting various CNS disorders. The company's research is focused on developing treatments for conditions such as [[migraine]], [[depression]], and [[Parkinson's disease]]. | ||
== | ==Corporate Structure== | ||
Trevena | Trevena is headquartered in [[Chesterbrook, Pennsylvania]], and operates with a team of experienced professionals in the fields of drug discovery, clinical development, and regulatory affairs. The company collaborates with academic institutions and other biopharmaceutical companies to enhance its research capabilities and accelerate the development of its drug candidates. | ||
==Related pages== | ==Related pages== | ||
* [[ | * [[Biopharmaceutical]] | ||
* [[ | * [[G protein-coupled receptor]] | ||
* [[ | * [[Opioid]] | ||
* [[Central nervous system]] | * [[Central nervous system]] | ||
| Line 34: | Line 30: | ||
[[Category:Companies based in Pennsylvania]] | [[Category:Companies based in Pennsylvania]] | ||
[[Category:Companies established in 2007]] | [[Category:Companies established in 2007]] | ||
[[Category: | [[Category:Pharmaceutical companies of the United States]] | ||
Latest revision as of 01:35, 7 March 2025
Trevena, Inc. is a biopharmaceutical company based in the United States that focuses on the development of novel therapeutics for the treatment of central nervous system (CNS) disorders. The company is known for its innovative approach to drug discovery, particularly in the area of G protein-coupled receptors (GPCRs).
History[edit]
Trevena, Inc. was founded in 2007 by a team of scientists and entrepreneurs with a vision to leverage cutting-edge research in GPCR biology to develop new therapies. The company was initially supported by venture capital funding and has since grown to become a publicly traded entity on the NASDAQ stock exchange under the ticker symbol TRVN.
Research and Development[edit]
Trevena's research and development efforts are centered around the modulation of GPCRs, which are a large family of cell surface receptors that play a crucial role in many physiological processes. The company employs a proprietary platform to design biased ligands, which selectively activate specific signaling pathways associated with GPCRs, potentially leading to improved therapeutic outcomes with fewer side effects.
Key Products[edit]
One of Trevena's most notable products is oliceridine, a novel opioid analgesic designed to provide effective pain relief with a reduced risk of adverse effects commonly associated with traditional opioids, such as respiratory depression and constipation. Oliceridine has been approved by the U.S. Food and Drug Administration (FDA) for the management of acute pain in adults.
Pipeline[edit]
Trevena continues to advance its pipeline of drug candidates targeting various CNS disorders. The company's research is focused on developing treatments for conditions such as migraine, depression, and Parkinson's disease.
Corporate Structure[edit]
Trevena is headquartered in Chesterbrook, Pennsylvania, and operates with a team of experienced professionals in the fields of drug discovery, clinical development, and regulatory affairs. The company collaborates with academic institutions and other biopharmaceutical companies to enhance its research capabilities and accelerate the development of its drug candidates.
